v3.26.1
SEGMENT REPORTING (Tables)
6 Months Ended
Jun. 30, 2026
SEGMENT REPORTING  
Schedule of Additional disaggregated significant segment expenses

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three Months Ended June 30

​

Six Months Ended June 30

​

2026

  ​ ​ ​

2025

  ​ ​ ​

2026

  ​ ​ ​

2025

R&D Employee Expenses

$

1,961

 

$

1,639

 

$

4,026

 

$

3,356

R&D Clinical Trial Expenses

​

1,955

 

​

1,605

​

​

3,167

 

​

2,641

R&D Manufacturing

​

766

​

​

356

​

​

1,595

​

​

832

R&D License Fees

​

1

​

​

—

​

​

1

​

​

438

G&A Professional Fees

​

1,537

​

​

2,045

​

​

2,694

​

​

3,002

G&A Employee Expenses

​

568

​

​

472

​

​

1,169

​

​

974

G&A Insurance and other

​

408

​

​

465

 

​

804

​

​

894

Other Segment Items *

​

(176)

 

​

(248)

 

​

(386)

 

​

(471)

Segment Loss

$

7,020

 

$

6,334

​

$

13,070

 

$

11,666

​

* - Other Segment Items included in net loss include finance income.